Document is current
Any future updates will be listed below
-
Authors
Hillary, Tom M. https://orcid.org/0000-0002-4497-8487
Vanhoutvin, Tine https://orcid.org/0009-0004-6269-6354
Peeters, Miet
Imbrechts, Maya https://orcid.org/0000-0002-4467-9831
Vanassche, Thomas https://orcid.org/0000-0002-7404-8918
Garmyn, Marjan https://orcid.org/0000-0001-9744-5038
Vermeire, Séverine https://orcid.org/0000-0001-9942-3019
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 20 February 2024
First Online: 7 March 2024
Declarations
:
: Tom Hillary has received consultancy from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sandoz, UCB Pharma; speaker fees from AbbVie, Almirall, Amgen, Biogen, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sanofi, UCB Pharma; research funding from AbbVie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Novartis, UCB Pharma. SV Has received grants from: AbbVie, J&J, Pfizer, Galapagos, Takeda and Has received consulting and/or speaking fees from AbbVie, AbolerIS Pharma, AgomAb, Alimentiv, Arena Pharmaceuticals, AstraZeneca, Avaxia, BMS, Boehringer Ingelheim, Celgene, CVasThera, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Imidomics, Janssen, J&J, Lilly, Materia Prima, MiroBio, Morphic, MrMHealth, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Surrozen, Takeda, Theravance, Tillots Pharma AG, Zealand Pharma. Tine Vanhoutvin, Miet Peeters, Maya Imbrechts, ThomasVanassche and Marjan Garmyn have nothing to disclose.
: Institutional Board Approval (s62301) was obtained prior to the start of this project; prior to enrolment, all patients signed informed consent. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.
